In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.
Melissa Burgess, MD
Advertisement
Articles by Melissa Burgess, MD
Advertisement
Latest Updated Articles
Dr. Burgess on Pembrolizumab in SarcomaJanuary 16th 2017
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer
4
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
5